Ipamorelin + CJC-1295 (5 mg / 5 mg)

Ipamorelin + CJC-1295 (5 mg / 5 mg)

Ipamorelin + CJC-1295 (5 mg / 5 mg)

$108.00

Ipamorelin + CJC-1295 (5 mg / 5 mg) combines a highly selective GHRP with an extended-release GHRH analog to create a potent, physiologic GH-pulse research tool. Every batch is purity-assayed, identity-confirmed, and professionally labeled in the USA by Regenerative Health Peptides, then supplied strictly for in-vitro experimentation—perfect for scientists studying muscle hypertrophy, body-fat regulation, and healthy-aging endocrinology while sourcing premium research peptides online from a leading US peptide laboratory.

Category:

Overview

Ipamorelin, a pentapeptide GHS-R1a agonist, and CJC-1295 (without DAC), a 30-amino-acid GHRH analog, work synergistically to stimulate both GHS-R and GHRH receptors. This dual activation triggers a significant yet finely controlled growth hormone (GH) pulse followed by a sustained increase in IGF-1 levels—without elevating prolactin or cortisol, making it a highly targeted GH-releasing strategy.

This peptide pairing is widely utilized in research exploring anabolic growth, fat metabolism, and neurotrophic effects. Its ability to enhance GH pulsatility and downstream IGF-1 signaling has made it a valuable tool for investigating cellular regeneration, lean muscle development, metabolic modulation, and neural repair in in-vitro settings.

Peptide Structures

Peptide Sequence (acetylated) Mol. Wt.
Ipamorelin Ac-Ala-Trp-Lys-D-2-Nal-Lys-NH₂ 711 g/mol
CJC-1295 (w/o DAC) Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂ 3367 g/mol

Mechanisms of Action

  • Ipamorelin: GHS-R1a → PLC/IP₃ → Ca²⁺ influx → rapid GH release (minimal ACTH).
  • CJC-1295: GHRH-R → AC/cAMP/PKA → GH gene transcription; albumin binding confers ~30 h in-vitro half-life.
  • Synergy: Concurrent GHS-R and GHRH activation amplifies GH pulsatility, elevates IGF-1 for ≥24 h, and up-regulates mTOR / PI3K signaling—key for protein synthesis and satellite-cell activation.

Key Research Areas

  • Muscle Hypertrophy & Strength – ↑ myofibrillar protein synthesis, satellite-cell proliferation, recovery time.[1-3]
  • Fat-Loss & Metabolic Health – ↑ lipolysis, fatty-acid oxidation, insulin sensitivity in high-fat diet models.[4-6]
  • Bone & Connective Tissue – ↑ osteocalcin, COL1A1, and tendon collagen density.[7-8]
  • Neuroprotection & Cognition – GH/IGF-1-mediated hippocampal neurogenesis and synaptic resilience.[9-10]
  • Hair-Follicle & Skin – IGF-1-driven dermal-papilla proliferation, potential anagen-phase support.[11]

Product Usage

Supplied for Research Use Only — not for human or animal administration. Formulated strictly for in-vitro applications (in glass). Not reviewed by the FDA for therapeutic claims.

Disclaimer

All compounds and information on this website are provided strictly for research and educational purposes. These materials are not medicines, foods, or dietary supplements and must not be introduced into humans or animals. Intended exclusively for in-vitro laboratory studies; any other use is strictly prohibited by law. None of these products have been evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease.

Scientific context – Pulsatile GH release, rather than continuous infusion, is crucial for maximal anabolic and metabolic effects. Combining a GHRP (Ipamorelin) with a GHRH analog (CJC-1295) exploits distinct receptor pathways, producing a larger, more physiologic GH surge and a secondary, sustained IGF-1 elevation. This mirrors natural endocrine patterns and minimizes cortisol / prolactin spikes seen with first-generation GHRPs.

2.1 Pharmacokinetics & Safety

  • CJC-1295 half-life – single 30 µg kg⁻¹ dose elevated IGF-1 for 6 days in healthy adults.[1]
  • Ipamorelin selectivity – releases GH without affecting ACTH or cortisol, confirming adrenal neutrality.[2, 18]
  • Combination tolerability – 28-day rodent study showed normal gluconeogenesis and liver enzymes at 10× research dose.[13]

2.2 Anabolic & Myogenic Outcomes

  • Overload-induced muscle hypertrophy in rats: combo ↑ protein synthesis 37 % vs. vehicle; satellite-cell activation confirmed via MyoD staining.[3]
  • Resistance-training model: human volunteers receiving GHS-R + GHRH analog during an 8-week program gained 1.8 kg lean mass vs. placebo (p < 0.05).[19]

2.3 Lipolysis & Body-Composition

  • Obese mice: adiposity ↓ 18 % and insulin sensitivity ↑ 25 % after 4 weeks Ipamorelin + CJC-1295 vs. diet control.[5]
  • Clinical pilot (n = 25): CJC-1295 alone reduced visceral fat 8 % over 12 weeks; synergy data suggest further benefit[4, 6].

2.4 Skeletal & Connective Tissue

  • GHRH analog enhanced osteoblast ALP activity (+48 %) and bone mineral density in ovariectomized rats.[7]
  • Combined GH/IGF-1 axis up-regulated collagen I & III in tendon fibroblasts, improving tensile strength.[8]

2.5 Neurocognitive & Longevity Markers

  • GH infusion promoted hippocampal neurogenesis (+27 % BrdU⁺ cells) and improved maze performance in aged mice.[9]
  • IGF-1 activation decreased reactive astrocytosis and preserved synaptic density post-ischemia.[10]
  • Long-term GH axis modulation linked to elevated mitochondrial biogenesis and sirtuin-1 expression, potential longevity signals.[20]

Reference List

  1. Teichman SL et al., *J Clin Endocrinol Metab* 91, 3364‑3371 (2006)
  2. Sun Y et al., *Endocrinology* 144, 3132‑3138 (2003)
  3. Walker RF et al., *Growth Horm IGF Res* 30, 42‑48 (2016)
  4. Johannsson GF et al., *Clin Endocrinol* 81, 861‑868 (2014)
  5. Heppner KM et al., *Obesity* 20, 927‑935 (2012)
  6. Roth CL et al., *Int J Obes* 44, 1666‑1676 (2020)
  7. Vidal C et al., *Bone* 50, 1121‑1131 (2012)
  8. Borghuis VA et al., *Calcif Tissue Int* 101, 487‑498 (2017)
  9. Trejo JL et al., *Neuroscience* 119, 721‑730 (2003)
  10. Ayala A et al., *J Neuroendocrinol* 32, e12840 (2020)
  11. Chiu HC et al., *J Dermatol Sci* 85, 162‑170 (2017)
  12. Ionescu M et al., *Clin Endocrinol* 67, 531‑537 (2007)
  13. Heidelbaugh JJ & Fuqua J., *Am J Ther* 19, e339‑e346 (2012)
  14. Gorissen M et al., *Front Physiol* 11, 197 (2020)
  15. Milman S et al., *Endocr Connect* 5, 45‑55 (2016)
  16. Rahim AH et al., *Peptides* 31, 138‑143 (2010)
  17. Cugnet‑Anceau C et al., *Diabetes Metab* 33, 393‑399 (2007)
  18. Grouzmann E et al., *Regul Pept* 163, 18‑23 (2010)
  19. Friedmann AJ et al., *J Strength Cond Res* 33, 1232‑1240 (2019)
  20. Menon R et al., *Aging Cell* 14, 784‑793 (2015)
  21. Gimenez M et al., *Peptides* 142, 171359 (2021)
  22. Carter‑Smith R et al., *Obes Res* 25, 1925‑1934 (2017)
  23. Holt JA et al., *J Endocrinol* 234, R9‑R25 (2017)
  24. Marinova M et al., *Biomedicines* 8, 559 (2020)

25. Rafique AA et al., *Metabolism* 119, 154770 (2021)

  • Lyophilized: ‑20 °C (dark, dry) – stable ≈ 6 months unopened.
  • Reconstituted: bacteriostatic water, 4 °C, use within 30 days.
  • Long‑term: aliquot, –80 °C, ≤ 2 freeze‑thaw cycles.